Skip to main content

Table 1 Correlation between circFBXL5 expression and the clinicopathological features of breast cancer patients

From: CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis

Clinicopathologic features Relative circFBXL5 level P value
High (%) Low (%)
Age (years)    0.2493
 ≥ 55 15 (55.6) 12 (44.4)  
 < 55 9 (75.0) 3 (25.0)  
Tumor size (cm)    0.0181*
 ≥ 3 10 (90.9) 1 (9.1)  
 < 3 14 (50.0) 14 (50.0)  
TNM stage    0.0052*
 I + II 12 (46.2) 14 (53.8)  
 III 12 (92.3) 1 (7.7)  
ER status 0.8759
 Negative 9 (60.0) 6 (40.0)  
 Positive 15 (62.5) 9 (37.5)  
PR status 0.6729
 Negative 8 (57.1) 6 (42.9)  
 Positive 16 (64.0) 9 (36.0)  
HER2 status 0.2677
 Negative 17 (680.0) 8 (32.0)  
 Positive 7 (50.0) 7 (50.0)  
  1. *P < 0.05